Drug Trial Radar · NCT03723395
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Last checked: Nov 20, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Sep 17, 2018
Primary completion
Dec 21, 2018
Study completion Dec 28, 2018
Sponsor
- Lead sponsor
- Seagen Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is being done to look at how tucatinib could affect the way other drugs work. This study will look at healthy volunteers and how tucatinib affects their liver enzymes. Liver enzymes can change how drugs work in the body. There are 5 parts to this study. Parts A and C are looking at how the body breaks down tucatinib when there are lower levels of certain liver enzymes. Part B is looking at how the body breaks down tucatinib when there are high levels of certain liver and stomach enzymes. Parts D and E are looking at how tucatinib could change the levels of some liver and stomach enzymes in the body. This will help us know more about how tucatinib should be given to patients.
Conditions
- Drug-drug Interaction
Interventions
tucatinibDrug
300mg dose, orally administered
itraconazoleDrug
200mg dose
rifampinDrug
600mg dose
gemfibrozilDrug
600mg tablets
repaglinideDrug
1mg dose
tolbutamideDrug
500mg dose
midazolamDrug
2mg dose
digoxinDrug
0.5 mg dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve (AUC) from time 0 to infinityTime frame: Up to 22 days
- AUC from time 0 to the time of the last quantifiable concentrationTime frame: Up to 22 days
- Percentage extrapolation in AUCTime frame: Up to 22 days
- Maximum observed concentrationTime frame: Up to 22 days
- Time of maximum observed concentrationTime frame: Up to 22 days
- Apparent terminal elimination half-lifeTime frame: Up to 22 days
- Apparent total clearanceTime frame: Up to 22 days
- Apparent volume of distributionTime frame: Up to 22 days
- Metabolite-to-parent ratio based on AUCTime frame: Up to 22 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit
Daytona Beach, Florida
Covance Clinical Research Unit
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.